Cargando…

EGFR-targeting peptide-coupled platinum(IV) complexes

The high mortality rate of lung cancer patients and the frequent occurrence of side effects during cancer therapy demonstrate the need for more selective and targeted drugs. An important and well-established target for lung cancer treatment is the occasionally mutated epidermal growth factor recepto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mayr, Josef, Hager, Sonja, Koblmüller, Bettina, Klose, Matthias H. M., Holste, Katharina, Fischer, Britta, Pelivan, Karla, Berger, Walter, Heffeter, Petra, Kowol, Christian R., Keppler, Bernhard K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443859/ https://www.ncbi.nlm.nih.gov/pubmed/28405842 http://dx.doi.org/10.1007/s00775-017-1450-7

Ejemplares similares

Synthesis, Characterization and in vitro Studies of a Cathepsin B‐Cleavable Prodrug of the VEGFR Inhibitor Sunitinib
por: Karnthaler‐Benbakka, Claudia, et al.
Publicado: (2018)

Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
por: Kastner, Alexander, et al.
Publicado: (2023)

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
por: Fronik, Philipp, et al.
Publicado: (2022)

Impact of Stepwise NH(2)-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention
por: Kowol, Christian R., et al.
Publicado: (2016)

Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands
por: Fronik, Philipp, et al.
Publicado: (2021)

Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
por: Pelivan, Karla, et al.
Publicado: (2018)

Liposomal formulations of anticancer copper(ii) thiosemicarbazone complexes
por: Mathuber, Marlene, et al.
Publicado: (2021)

A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt(IV) Complexes under Physiological Conditions
por: Kastner, Alexander, et al.
Publicado: (2019)

Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney
por: Legin, A. A., et al.
Publicado: (2016)

Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo
por: Schueffl, Hemma, et al.
Publicado: (2021)

Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling
por: Miklos, Walter, et al.
Publicado: (2016)

Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs
por: Mathuber, Marlene, et al.
Publicado: (2020)

An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo
por: Mayr, Josef, et al.
Publicado: (2017)

Human serum albumin as a copper source for anticancer thiosemicarbazones
por: Schaier, Martin, et al.
Publicado: (2023)

Influence of the Fatty Acid Metabolism on the Mode of Action of a Cisplatin(IV) Complex with Phenylbutyrate as Axial Ligands
por: Mendrina, Theresa, et al.
Publicado: (2023)

Behavior of platinum(iv) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation†
por: Schreiber-Brynzak, Ekaterina, et al.
Publicado: (2016)

Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux
por: Bormio Nunes, Julia H., et al.
Publicado: (2020)

Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance
por: Pósa, Vivien, et al.
Publicado: (2022)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
por: Bielec, Bjoern, et al.
Publicado: (2020)

Platinum(IV)-Loaded Degraded Glycol Chitosan as Efficient Platinum(IV) Drug Delivery Platform
por: Lerchbammer-Kreith, Yvonne, et al.
Publicado: (2023)

The thiosemicarbazone Me(2)NNMe(2) induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition
por: Hager, Sonja, et al.
Publicado: (2018)

Combination of Drug Delivery Properties of PAMAM Dendrimers and Cytotoxicity of Platinum(IV) Complexes—A More Selective Anticancer Treatment?
por: Lerchbammer-Kreith, Yvonne, et al.
Publicado: (2023)

Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones
por: Heffeter, Petra, et al.
Publicado: (2012)

Diamminetetrakis(carboxylato)platinum(IV) Complexes – Synthesis, Characterization, and Cytotoxicity
por: Hoffmeister, Björn R, et al.
Publicado: (2012)

Structure elucidation and quantification of the reduction products of anticancer Pt(iv) prodrugs by electrochemistry/mass spectrometry (EC-MS)
por: Frensemeier, L. M., et al.
Publicado: (2018)

Improving the Stability of Maleimide–Thiol Conjugation for Drug Targeting
por: Lahnsteiner, Marianne, et al.
Publicado: (2020)

Osmium(IV) complexes with 1H- and 2H-indazoles: Tautomer identity versus spectroscopic properties and antiproliferative activity
por: Büchel, Gabriel E., et al.
Publicado: (2012)

Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition
por: Kubista, Bernd, et al.
Publicado: (2017)

Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients
por: Spitzwieser, Melanie, et al.
Publicado: (2016)

The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects
por: Berasaluce, Iker, et al.
Publicado: (2019)

NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
por: Trondl, Robert, et al.
Publicado: (2012)

Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SEC–ICP–MS
por: Klose, Matthias H. M., et al.
Publicado: (2018)

Biological activity of Pt(IV) prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis
por: Alonso-de Castro, Silvia, et al.
Publicado: (2018)

Synthesis and Characterization of New Ethylenediamine Platinum(IV) Complexes Containing Lipophilic Carboxylate Ligands
por: Galanski, M., et al.
Publicado: (1995)

Copper-Catalyzed Glutathione Oxidation is Accelerated by the Anticancer Thiosemicarbazone Dp44mT and Further Boosted at Lower pH
por: Falcone, Enrico, et al.
Publicado: (2022)

The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs – an HPLC-ICP-MS study
por: Theiner, Sarah, et al.
Publicado: (2018)

Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin
por: Varbanov, Hristo, et al.
Publicado: (2011)

Theoretical Investigations and Density Functional Theory Based Quantitative Structure–Activity Relationships Model for Novel Cytotoxic Platinum(IV) Complexes
por: Varbanov, Hristo P., et al.
Publicado: (2012)

Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074
por: Englinger, Bernhard, et al.
Publicado: (2018)

Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy
por: Filak, Lukas K., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ceqp81bqrq4vouukp68as5q6es